Back to search

Democritus University of Thrace (DUTH)

Ο ρόλος των CD8+ T λεμφοκυττάρων στην εξέλιξη και πρόγνωση των μυελικών νεοπλασιών

Abstract

dc:description

Myelodysplastic neoplasms (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) are myeloid neoplasms in which interactions between neoplastic and immune cells play an important role. Azacitidine (AZA) is the standard of care for patients deemed ineligible for intensive chemotherapy and/or hematopoietic stem cell transplantation. However, to date, no biomarkers have been identified that can reliably predict the progression from MDS or CMML to AML, nor the response to AZA treatment. By employing mass cytometry, we performed an in-depth immunophenotypic analysis of pre-treatment bone marrow (BM) samples, which revealed substantial qualitative and quantitative differences within T lymphocyte subsets across patient groups. Notably, the frequency of a distinct CD8+ T cell subset, defined as CD57+CXCR3+CCR7-CD45RA+, was increased in AML and CMML patients compared to those with MDS. This finding was subsequently confirmed by flow cytometry in an independent patient cohort. Furthermore, patients with higher-risk MDS (HR-MDS) and AML who did not respond to AZA exhibited increased baseline levels of the CD57+CXCR3+CD8+ T cell subset compared to responders. Aiming to evaluate the impact of AZA treatment on this subset, we performed immunophenotypic analysis of paired BM samples, collected before treatment initiation and after six cycles of AZA treatment, which revealed a significant post-treatment expansion of CD57+CXCR3+CD8+ T cells exclusively in non-responders, while no significant changes were observed in responders. Moreover, a baseline frequency of CD57+CXCR3+CD8+ T cells exceeding 29% was correlated with inferior overall survival (OS). Notably, these findings were evident only in HR-MDS and AML patients, whereas no differences were observed in CMML patients, suggesting disease-specific immune dynamics. Based on these findings, we further engaged scRNA-seq to assess the transcriptional landscape of BM-derived CD8+ T cells from patients with HR-MDS and AML at the highest possible resolution, aiming to identify molecular signatures associated with treatment response. Transcriptomic analysis of the identified cytotoxic CD8+ T cell clusters revealed distinct gene expression profiles based on treatment outcome. Specifically, responders exhibited upregulation of genes involved in IFN-related pathways, whereas non-responders displayed enrichment of the TGF-β signaling pathway. These molecular signatures were further associated with an enhanced cytotoxic gene expression profile within the cytotoxic T cell clusters of responders. Collectively, these findings highlight the crucial interplay between leukemic and immune cells in disease progression and treatment response, underscoring the pivotal role of CD8+ T cells in shaping the efficacy of AZA therapy.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Tasis, Athanasios
  • Τάσης, Αθανάσιος

Subjects

dc:subject × 32

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/58605

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Tasis, Athanasios; Τάσης, Αθανάσιος. Ο ρόλος των CD8+ T λεμφοκυττάρων στην εξέλιξη και πρόγνωση των μυελικών νεοπλασιών. Democritus University of Thrace (DUTH), 2025. http://hdl.handle.net/10442/hedi/58605